Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of regorafenib in pretreated advanced melanoma
2022-001291-34Phase 2Active
- Sponsor
- UZ Brussel
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in melanoma, sponsored by UZ Brussel. Primary endpoint: Objective response rate. Started May 2022; status: active.
02
Drugs
regorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-001291-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001291-34.